ALK-Abelló A/S (AKBLF) Q1 2026 Earnings Call May 4, 2026 11:00 AM EDT
Company Participants
Per Plotnikof – VP of Corporate Communications, Investor Relations & Strategic Planning and Head of IR
Peter Halling – President, CEO & Member of Management Board
Claus Solje – Executive VP, CFO & Member of Management Board
Conference Call Participants
Thomas Bowers – SEB, Research Division
Benjamin Jackson – Jefferies LLC, Research Division
Jesper Ingildsen – DNB Carnegie, Research Division
Sushila Hernandez – Kempen & Co. N.V., Research Division
Peter Ankersen – Nordea Markets, Research Division
Presentation
Per Plotnikof
VP of Corporate Communications, Investor Relations & Strategic Planning and Head of IR
Hello, everyone, and welcome to this presentation of ALK’s Q1 results. Thank you all for joining us. Let’s turn to Slide #2 with an introduction to the speakers and the agenda.
My name is Per Plotnikof, I’m Head of Investor Relations. And with me are CEO, Peter Halling; and CFO, Claus Steensen Solje. Peter and Claus will walk you through the highlights, markets, product trends and financial. And after a strategic update, where we’ll focus on peanut allergy, our respiratory tablets and the EURneffy rollout, we will turn to the full year outlook. As usual, we will end the call with a Q&A session. And to get started, I’ll hand you over to Peter on Slide 3. Please go ahead, Peter.
Peter Halling
President, CEO & Member of Management Board
Thank you, Per. Thank you all for taking the time to listen into this call. ALK had a very solid start to the year with revenue and earnings comfortably exceeding the upper end of the full year guidance range. EBIT grew by 22%, yielding a margin of 32% on the back of an 18% revenue growth to DKK 1.8 billion. For the first time ever, ALK’s total tablet sales exceeded DKK 1 billion in a single quarter.
